REGENERON PHARMACEUTICALS, INC. (REGN) stock — the fundamentals (P/E, market cap, valuation) and every material event, decoded in plain English.
Key numbers for REGENERON PHARMACEUTICALS, INC. (REGN): P/E ratio, market cap, profit margins, returns, and whether the stock looks cheap or expensive versus its own 5-year range.
AllSight quality score: 60/100 — a percentile rank of REGENERON PHARMACEUTICALS, INC.’s fundamentals against Manufacturing peers, weakest on management. A quality ranking, not a price prediction.
| Market cap | $75.7B |
| P / E | 17.5× |
| P / S | 4.9× |
| EV / EBITDA | 17.4× |
| Gross margin | 84.9% |
| Operating margin | 24.7% |
| Net margin | 27.9% |
| Return on equity | 13.7% |
| ROIC | 10.0% |
| Revenue growth | 9.3% |
| Debt / equity | 0.1× |
| Dividend yield | 0.5% |
Is REGENERON PHARMACEUTICALS, INC. overvalued? P/E looks fair vs its 5-year range; P/S looks fair vs its 5-year range; EV/EBITDA looks fair vs its 5-year range; P/B looks undervalued vs its 5-year range.
Independent of the events above — derived from REGENERON PHARMACEUTICALS, INC.’s own financial statements and shown as context, never as advice.
About AllSight · Editorial standards & method · Contact